Search research articles
Contact Us
Filters
Showing results (41-50 of 66) with videos related to
Page
of 7
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 26, 2023
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy
Kai He, David Berz, Shirish M Gadgeel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 11, 2022
Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer
Joshua K Sabari, Vamsidhar Velcheti, Kazuhide Shimizu, et al.
Journal of Medicinal Chemistry
|
December 29, 2023
Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray Cocrystallography
Christopher R Smith, Dan Chen, James G Christensen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 13, 2025
Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial
Marcelo V Negrao, Alvaro G Paula, David Molkentine, et al.
Journal of Medicinal Chemistry
|
January 18, 2022
Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of <i>MTAP</i>-Deleted Cancers
Christopher R Smith, Ruth Aranda, Thomas P Bobinski, et al.
International Journal of Cancer
|
July 9, 2015
A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer
John J Arcaroli, W M Tai, Ryan McWilliams, et al.
Science Signaling
|
November 13, 2014
Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR
Peter J Belmont, Ping Jiang, Trevor D McKee, et al.
European Urology Oncology
|
December 17, 2023
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma
Pavlos Msaouel, Randy F Sweis, Manojkumar Bupathi, et al.
Journal of Medicinal Chemistry
|
July 14, 2022
Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction
John M Ketcham, Jacob Haling, Shilpi Khare, et al.
Nature Communications
|
May 10, 2023
Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma
Jose A Karam, Pavlos Msaouel, Cara L Haymaker, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 66) with videos related to
Sort By:
Page
of 7
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 26, 2023
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy
Kai He, David Berz, Shirish M Gadgeel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 11, 2022
Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer
Joshua K Sabari, Vamsidhar Velcheti, Kazuhide Shimizu, et al.
Journal of Medicinal Chemistry
|
December 29, 2023
Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray Cocrystallography
Christopher R Smith, Dan Chen, James G Christensen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 13, 2025
Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial
Marcelo V Negrao, Alvaro G Paula, David Molkentine, et al.
Journal of Medicinal Chemistry
|
January 18, 2022
Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of <i>MTAP</i>-Deleted Cancers
Christopher R Smith, Ruth Aranda, Thomas P Bobinski, et al.
International Journal of Cancer
|
July 9, 2015
A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer
John J Arcaroli, W M Tai, Ryan McWilliams, et al.
Science Signaling
|
November 13, 2014
Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR
Peter J Belmont, Ping Jiang, Trevor D McKee, et al.
European Urology Oncology
|
December 17, 2023
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma
Pavlos Msaouel, Randy F Sweis, Manojkumar Bupathi, et al.
Journal of Medicinal Chemistry
|
July 14, 2022
Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction
John M Ketcham, Jacob Haling, Shilpi Khare, et al.
Nature Communications
|
May 10, 2023
Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma
Jose A Karam, Pavlos Msaouel, Cara L Haymaker, et al.
Page
of 7